{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:18:57Z","timestamp":1788920337352,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Postdoctoral Fund of Sichuan Provincial People's Hospital Research Fund","award":["2022BH23"],"award-info":[{"award-number":["2022BH23"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Glioma is a highly malignant primary neoplasm of the central nervous system. Temozolomide (TMZ) is the first-line chemotherapeutic drug for glioma, commonly employed in conjunction with radiotherapy to improve overall patient outcomes, but the resistance significantly limits its efficacy. Identifying regulatory molecular targets that influence glioma progression and TMZ sensitivity is critical improve treatment outcomes. Even though SIRT7 has been implicated in tumorigenesis, the regulatory mechanisms of SIRT7 and the role of its upstream microRNAs in glioma progression remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We constructed SIRT7 knockdown and overexpression in glioma cells lines, and detected the tumor phenotypes. Moreover, both in - vitro and in - vivo experiments were carried out to assess the influence of SIRT7 expression levels on the treatment effectiveness of temozolomide (TMZ) in glioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our research indicated that SIRT7 is significantly over - expressed in tumor specimens obtained from glioma patients. This over - expression is associated with the tumor stage and a unfavorable prognosis. In addition, reducing the expression of SIRT7 can effectively impede the advancement of glioma cells. It has been confirmed that SIRT7 serves as a downstream target of miR-148a-3p. When there is an upregulation of miR-148a-3p, it suppresses the proliferation of glioma cells. Moreover, it causes tumor cells to become arrested in the G1 phase and stimulates cell death via apoptosis. Interestingly, SIRT7 knockdown enhanced TMZ-induced cytotoxicity in vitro and potentiated TMZ antitumor effects in glioblastoma xenografts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The aforementioned results suggested the miR-148a-3p\/SIRT7 axis drives glioma progression and modulates TMZ sensitivity, and targeting this axis may represent a promising therapeutic approach to overcome TMZ resistance in glioma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-025-05303-7","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T07:39:19Z","timestamp":1760945959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["MiR-148a-3p\/SIRT7 axis promotes glioma progression and regulates temozolomide chemosensitivity"],"prefix":"10.1007","volume":"176","author":[{"given":"Kai","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mou","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"5303_CR1","doi-asserted-by":"crossref","unstructured":"Bagley SJ, Desai AS, Fraietta JA et al (2025) Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial. Nat Med","DOI":"10.1038\/s41591-025-03745-0"},{"key":"5303_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.canlet.2020.10.050","volume":"499","author":"T Jiang","year":"2021","unstructured":"Jiang T, Nam DH, Ram Z et al (2021) Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett 499:60\u201372","journal-title":"Cancer Lett"},{"key":"5303_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejphar.2019.03.005","volume":"852","author":"S Ma","year":"2019","unstructured":"Ma S, Fu T, Zhao S, Gao M (2019) MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. Eur J Pharmacol 852:42\u201350","journal-title":"Eur J Pharmacol"},{"issue":"23","key":"5303_CR4","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/s41388-025-03454-5","volume":"44","author":"Y Chen","year":"2025","unstructured":"Chen Y, Ding K, Zheng S et al (2025) Post-translational modifications in DNA damage repair: mechanisms underlying Temozolomide resistance in glioblastoma. Oncogene 44(23):1781\u20131792","journal-title":"Oncogene"},{"issue":"5","key":"5303_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.trecan.2025.01.007","volume":"11","author":"TA Mishchenko","year":"2025","unstructured":"Mishchenko TA, Olajide OJ, Gorshkova EN, Vedunova MV, Krysko DV (2025) Regulated cell death modalities: breaking resistance of Temozolomide glioblastoma therapy. Trends Cancer 11(5):430\u2013432","journal-title":"Trends Cancer"},{"issue":"1","key":"5303_CR6","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41467-021-21407-w","volume":"12","author":"N Ochocka","year":"2021","unstructured":"Ochocka N, Segit P, Walentynowicz KA et al (2021) Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. Nat Commun 12(1):1151","journal-title":"Nat Commun"},{"issue":"1","key":"5303_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/neuonc\/noaa180","volume":"23","author":"JJ Miller","year":"2021","unstructured":"Miller JJ, Fink A, Banagis JA et al (2021) Sirtuin activation targets IDH-mutant tumors. Neuro Oncol 23(1):53\u201362","journal-title":"Neuro Oncol"},{"key":"5303_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.plrev.2025.03.020","volume":"53","author":"D Hajra","year":"2025","unstructured":"Hajra D, Chakravortty D (2025) Sirtuins as modulators of infection outcomes in the battle of host-pathogen dynamics. Phys Life Rev 53:225\u2013235","journal-title":"Phys Life Rev"},{"issue":"1","key":"5303_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41419-025-07549-5","volume":"16","author":"T Yu","year":"2025","unstructured":"Yu T, Ding C, Peng J et al (2025) SIRT7-mediated NRF2 deacetylation promotes antioxidant response and protects against chemodrug-induced liver injury. Cell Death Dis 16(1):232","journal-title":"Cell Death Dis"},{"issue":"1","key":"5303_CR10","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1038\/s41467-025-58317-0","volume":"16","author":"Z Hu","year":"2025","unstructured":"Hu Z, Tang M, Huang Y et al (2025) SIRT7 facilitates endometrial cancer progression by regulating PTEN stability in an estrogen-dependent manner. Nat Commun 16(1):2989","journal-title":"Nat Commun"},{"issue":"1","key":"5303_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41392-023-01314-w","volume":"8","author":"X Yi","year":"2023","unstructured":"Yi X, Wang H, Yang Y et al (2023) SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR activation. Signal Transduct Target Ther 8(1):107","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"5303_CR12","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.7150\/thno.18804","volume":"7","author":"M Tang","year":"2017","unstructured":"Tang M, Lu X, Zhang C et al (2017) Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer. Theranostics 7(5):1346\u20131359","journal-title":"Theranostics"},{"issue":"4","key":"5303_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41580-024-00805-0","volume":"26","author":"H Kim","year":"2025","unstructured":"Kim H, Lee YY, Kim VN (2025) The biogenesis and regulation of animal MicroRNAs. Nat Rev Mol Cell Biol 26(4):276\u2013296","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5303_CR14","doi-asserted-by":"publisher","first-page":"119709","DOI":"10.1016\/j.jep.2025.119709","volume":"346","author":"Y Ma","year":"2025","unstructured":"Ma Y, Song B, Peng J et al (2025) Cornua cervi degelatinatum inhibits breast cancer stem-like cell properties and metastasis via miR-148a-3p-mediated TGF-\u03b2\/Smad2 pathway. J Ethnopharmacol 346:119709","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"5303_CR15","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1111\/cas.15399","volume":"113","author":"C OuYang","year":"2022","unstructured":"OuYang C, Shu G, Liu J et al (2022) HDAC5, negatively regulated by miR-148a-3p, promotes colon cancer cell migration. Cancer Sci 113(8):2560\u20132574","journal-title":"Cancer Sci"},{"issue":"11","key":"5303_CR16","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1038\/s41401-022-00893-8","volume":"43","author":"L Liang","year":"2022","unstructured":"Liang L, Xu WY, Shen A et al (2022) Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9. Acta Pharmacol Sin 43(11):2946\u20132955","journal-title":"Acta Pharmacol Sin"},{"key":"5303_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.omtn.2021.11.019","volume":"27","author":"L Zeng","year":"2022","unstructured":"Zeng L, Jiang H, Ashraf GM et al (2022) Implications of miR-148a-3p\/p35\/PTEN signaling in Tau hyperphosphorylation and autoregulatory feedforward of Akt\/CREB in alzheimer\u2019s disease. Mol Ther Nucleic Acids 27:256\u2013275","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"5303_CR18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.21037\/atm-21-2402","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang C, Lu W, Chen R, Yu M (2021) Establishment of a prognostic-related MicroRNAs risk model for glioma by bioinformatics analysis. Ann Transl Med 9(12):1022","journal-title":"Ann Transl Med"},{"issue":"1","key":"5303_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3892\/mmr.2022.12895","volume":"27","author":"B Schneider","year":"2023","unstructured":"Schneider B, Lamp N, Zimpfer A, Henker C, Erbersdobler A (2023) Comparing tumor MicroRNA profiles of patients with long\u2013 and short\u2013term\u2013surviving glioblastoma. Mol Med Rep 27(1):8","journal-title":"Mol Med Rep"},{"issue":"17","key":"5303_CR20","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.7150\/thno.100667","volume":"14","author":"H Shen","year":"2024","unstructured":"Shen H, Qi X, Hu Y et al (2024) Targeting sirtuins for cancer therapy: epigenetics modifications and beyond. Theranostics 14(17):6726\u20136767","journal-title":"Theranostics"},{"key":"5303_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.semcancer.2018.11.003","volume":"57","author":"S Zhu","year":"2019","unstructured":"Zhu S, Dong Z, Ke X et al (2019) The roles of sirtuins family in cell metabolism during tumor development. Semin Cancer Biol 57:59\u201371","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"5303_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41418-019-0369-7","volume":"27","author":"W Zhang","year":"2020","unstructured":"Zhang W, Feng Y, Guo Q et al (2020) SIRT1 modulates cell cycle progression by regulating CHK2 acetylation-phosphorylation. Cell Death Differ 27(2):482\u2013496","journal-title":"Cell Death Differ"},{"issue":"8","key":"5303_CR23","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1080\/15548627.2021.2007027","volume":"18","author":"J Yao","year":"2022","unstructured":"Yao J, Wang J, Xu Y et al (2022) CDK9 Inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma. Autophagy 18(8):1879\u20131897","journal-title":"Autophagy"},{"issue":"22","key":"5303_CR24","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1016\/j.devcel.2022.10.008","volume":"57","author":"T Kataura","year":"2022","unstructured":"Kataura T, Sedlackova L, Otten EG et al (2022) Autophagy promotes cell survival by maintaining NAD levels. Dev Cell 57(22):2584\u20132598e2511","journal-title":"Dev Cell"},{"key":"5303_CR25","doi-asserted-by":"publisher","first-page":"176155","DOI":"10.1016\/j.ejphar.2023.176155","volume":"963","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wei H, Li J (2024) A review on SIRT3 and its natural small molecule activators as a potential preventive and therapeutic target. Eur J Pharmacol 963:176155","journal-title":"Eur J Pharmacol"},{"key":"5303_CR26","doi-asserted-by":"publisher","first-page":"1281730","DOI":"10.3389\/fcell.2023.1281730","volume":"11","author":"BN Vazquez","year":"2023","unstructured":"Vazquez BN, Fern\u00e1ndez-Duran I, Hernandez Y et al (2023) SIRT7 and p53 interaction in embryonic development and tumorigenesis. Front Cell Dev Biol 11:1281730","journal-title":"Front Cell Dev Biol"},{"key":"5303_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.semcancer.2024.10.005","volume":"106\u2013107","author":"R Pun","year":"2024","unstructured":"Pun R, Kumari N, Monieb RH, Wagh S, North BJ (2024) BubR1 and SIRT2: insights into aneuploidy, aging, and cancer. Semin Cancer Biol 106\u2013107:201\u2013216","journal-title":"Semin Cancer Biol"},{"key":"5303_CR28","doi-asserted-by":"publisher","first-page":"102496","DOI":"10.1016\/j.arr.2024.102496","volume":"101","author":"J Nah\u00e1lkov\u00e1","year":"2024","unstructured":"Nah\u00e1lkov\u00e1 J (2024) On the interface of aging, cancer, and neurodegeneration with SIRT6 and L1 retrotransposon protein interaction network. Ageing Res Rev 101:102496","journal-title":"Ageing Res Rev"},{"issue":"23","key":"5303_CR29","doi-asserted-by":"publisher","first-page":"e152868","DOI":"10.1172\/JCI152868","volume":"132","author":"N Luo","year":"2022","unstructured":"Luo N, Mosialou I, Capulli M et al (2022) A neuronal action of Sirtuin 1 suppresses bone mass in young and aging mice. J Clin Invest 132(23):e152868","journal-title":"J Clin Invest"},{"issue":"1","key":"5303_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41413-025-00413-4","volume":"13","author":"Y Deng","year":"2025","unstructured":"Deng Y, Hou M, Wu Y et al (2025) SIRT3-PINK1-PKM2 axis prevents osteoarthritis via mitochondrial renewal and metabolic switch. Bone Res 13(1):36","journal-title":"Bone Res"},{"issue":"17","key":"5303_CR31","doi-asserted-by":"publisher","first-page":"e2404734","DOI":"10.1002\/advs.202404734","volume":"12","author":"R Zi","year":"2025","unstructured":"Zi R, Zhao X, Liu L et al (2025) Metabolic-Immune suppression mediated by the SIRT1-CX3CL1 axis induces functional enhancement of regulatory T cells in colorectal carcinoma. Adv Sci (Weinh) 12(17):e2404734","journal-title":"Adv Sci (Weinh)"},{"issue":"694","key":"5303_CR32","doi-asserted-by":"publisher","first-page":"eabn9674","DOI":"10.1126\/scitranslmed.abn9674","volume":"15","author":"N Kartha","year":"2023","unstructured":"Kartha N, Gianopulos JE, Schrank Z et al (2023) Sirtuin 6 is required for the integrated stress response and resistance to Inhibition of transcriptional cyclin-dependent kinases. Sci Transl Med 15(694):eabn9674","journal-title":"Sci Transl Med"},{"issue":"12","key":"5303_CR33","doi-asserted-by":"publisher","first-page":"115060","DOI":"10.1016\/j.celrep.2024.115060","volume":"43","author":"X Zhang","year":"2024","unstructured":"Zhang X, Ling C, Xiong Z et al (2024) Desuccinylation of TBK1 by SIRT5 regulates inflammatory response of macrophages in sepsis. Cell Rep 43(12):115060","journal-title":"Cell Rep"},{"issue":"10","key":"5303_CR34","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41418-022-00991-4","volume":"29","author":"I Masgras","year":"2022","unstructured":"Masgras I, Cannino G, Ciscato F et al (2022) Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD(+) and SIRT3. Cell Death Differ 29(10):1996\u20132008","journal-title":"Cell Death Differ"},{"issue":"9","key":"5303_CR35","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/s41401-021-00841-y","volume":"43","author":"HF Yuan","year":"2022","unstructured":"Yuan HF, Zhao M, Zhao LN et al (2022) PRMT5 confers lipid metabolism reprogramming, tumour growth and metastasis depending on the SIRT7-mediated desuccinylation of PRMT5 K387 in tumours. Acta Pharmacol Sin 43(9):2373\u20132385","journal-title":"Acta Pharmacol Sin"},{"key":"5303_CR36","doi-asserted-by":"publisher","first-page":"1557384","DOI":"10.3389\/fcell.2025.1557384","volume":"13","author":"P Huang","year":"2025","unstructured":"Huang P, Qin D, Qin Y, Tao S, Liu G (2025) SIRT3\/6\/7: promising therapeutic targets for pulmonary fibrosis. Front Cell Dev Biol 13:1557384","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"5303_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5483\/BMBRep.2023-0187","volume":"57","author":"Y Kim","year":"2024","unstructured":"Kim Y, Kang BE, Gariani K et al (2024) Loss of hepatic Sirt7 accelerates diethylnitrosamine (DEN)-induced formation of hepatocellular carcinoma by impairing DNA damage repair. BMB Rep 57(2):98\u2013103","journal-title":"BMB Rep"},{"issue":"3","key":"5303_CR38","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1053\/j.gastro.2019.10.025","volume":"158","author":"J Xiang","year":"2020","unstructured":"Xiang J, Zhang N, Sun H et al (2020) Disruption of SIRT7 increases the efficacy of checkpoint inhibitor via MEF2D regulation of programmed cell death 1 ligand 1 in hepatocellular carcinoma cells. Gastroenterology 158(3):664\u2013678e624","journal-title":"Gastroenterology"},{"issue":"23","key":"5303_CR39","doi-asserted-by":"publisher","first-page":"15119","DOI":"10.3390\/ijms232315119","volume":"23","author":"A Poniewierska-Baran","year":"2022","unstructured":"Poniewierska-Baran A, Warias P, Zgutka K (2022) Sirtuins (SIRTs) as a novel target in gastric cancer. Int J Mol Sci 23(23):15119","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5303_CR40","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.7150\/ijbs.75340","volume":"19","author":"Q Huo","year":"2023","unstructured":"Huo Q, Chen S, Zhuang J, Quan C, Wang Y, Xie N (2023) SIRT7 downregulation promotes breast cancer metastasis via LAP2\u03b1-Induced chromosomal instability. Int J Biol Sci 19(5):1528\u20131542","journal-title":"Int J Biol Sci"},{"issue":"12","key":"5303_CR41","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41419-024-07321-1","volume":"15","author":"Y Cao","year":"2024","unstructured":"Cao Y, Wang S, Ma J et al (2024) Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells. Cell Death Dis 15(12):931","journal-title":"Cell Death Dis"},{"issue":"1","key":"5303_CR42","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41419-025-07656-3","volume":"16","author":"A Song","year":"2025","unstructured":"Song A, Liu B, Li W et al (2025) Competitive binding between DDX21 and SIRT7 enhances NAT10-mediated ac(4)C modification to promote colorectal cancer metastasis and angiogenesis- DDX21 promotes colorectal cancer metastasis. Cell Death Dis 16(1):353","journal-title":"Cell Death Dis"},{"key":"5303_CR43","doi-asserted-by":"publisher","first-page":"217109","DOI":"10.1016\/j.canlet.2024.217109","volume":"598","author":"K Chen","year":"2024","unstructured":"Chen K, Li T, Diao H et al (2024) SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression. Cancer Lett 598:217109","journal-title":"Cancer Lett"},{"issue":"6","key":"5303_CR44","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.7150\/ijbs.66184","volume":"18","author":"X Zhang","year":"2022","unstructured":"Zhang X, Chen F, Huang P et al (2022) Exosome-depleted MiR-148a-3p derived from hepatic stellate cells promotes tumor progression via ITGA5\/PI3K\/Akt axis in hepatocellular carcinoma. Int J Biol Sci 18(6):2249\u20132260","journal-title":"Int J Biol Sci"},{"issue":"12","key":"5303_CR45","first-page":"5647","volume":"11","author":"SW Cai","year":"2018","unstructured":"Cai SW, Han Y, Wang GP (2018) miR-148a-3p exhaustion inhibits necrosis by regulating PTEN in acute pancreatitis. Int J Clin Exp Pathol 11(12):5647\u20135657","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05303-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05303-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05303-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:26:24Z","timestamp":1781612784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05303-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5303"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05303-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with The principles of The declaration of Helsinki.Our project was authorized by The ethics committee of Chinese PLA general Hospital. Also, we got the informed written consents from each patient prior to our study. Mouse experiment was approved by Animal Care and Use Committee of Chinese PLA General Hospital and conducted referring to the national standard of laboratory animal use and care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}